It’s been a busy week for personalized medicine! First, the FDA announced a black box for Plavix warning physicians of treament failures in CYP2C19 poor metabolizers representing up to 14% of their patients. See http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm for more details. Plavix is currently one of the most commonly prescribed medications in the world so the impact of this [...]
Filed under: Personalized Medicine | Leave a Comment »
